Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 01, 2017 | July 06, 2017 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director | February 18, 2020 | February 19, 2020 |
| Immatics N.V.IMTX · Entity 4718 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 01, 2017 · Filed July 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 59,064 |
Reported balance
After 2017-07-01 transaction · row 1
1 source rowRow 1 · 2017-07-01 · Tax withholding · Disposed 613 · Balance 59,064 |
| Common shares without par valueSEC Table I · non-derivative | IndirectHeather L. Mason 2016 GRAT | 70,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 70,000 |
Assertio Therapeutics, Inc
Report date February 18, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,394 |
Reported balance
After 2020-02-18 transaction · row 1
1 source rowRow 1 · 2020-02-18 · Exercise / conversion · Acquired 14,394 · Balance 14,394 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-18 | Direct | 28,788 |
Reported balance
After 2020-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-18 · Exercise / conversion · Disposed 14,394 · Balance 28,788 F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F2: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date.
F3: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Immatics N.V.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2036-06-15 | Direct | 48,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 48,000 · Balance 48,000 F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Assertio Holdings, Inc.
Report date June 16, 2026 · Filed June 16, 2026
Section 16 reporting ended · disclosed 2026-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Other · Disposed 20,944 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-06-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-16 · Other · Disposed 6,666 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-16 · Disposition to issuer · Disposed 36,666 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2]
F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,639 | $54.33 | $89,046.87 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,078 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.32 | $5,432.00 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,717 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,456 | $54.30 | $79,060.80 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,817 Read SEC document |
| May 01, 2011 Filed May 3, 2011 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,486 | $52.04 | $181,411.44 |
DisclosureSEC source: 0001179110-11-007247 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,273 Read SEC document |
| April 28, 2011 Filed Apr 29, 2011 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,640 | $0.00 Strike: $52.04 | $0.00 |
DisclosureSEC source: 0001179110-11-007062 · edgar.xml · derivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,640 shares Expires 2011-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 28, 2011 Filed Apr 29, 2011 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,640 | $52.25 | $555,940.00 |
DisclosureSEC source: 0001179110-11-007062 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,759 Read SEC document |
| April 28, 2011 Filed Apr 29, 2011 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,640 | $52.04 | $553,721.56 |
DisclosureSEC source: 0001179110-11-007062 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,845 | $47.94 | $88,449.30 |
DisclosureSEC source: 0001179110-11-003914 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,759 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,042 | $47.64 | $335,480.88 |
DisclosureSEC source: 0001179110-11-003914 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,604 Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 31,200 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-11-003281 · edgar.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,200 Underlying: Common shares · 31,200 shares Expires 2021-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,400 on 02/18/2012, 10,400 on 02/18/2013, and 10,400 on 02/18/2014. Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 22,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-003281 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,646 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 29, 2010 Filed Jul 1, 2010 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,334 | $47.18 | $110,118.12 |
DisclosureSEC source: 0001179110-10-011198 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,446 Read SEC document |
| May 01, 2010 Filed May 4, 2010 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,486 | $51.16 | $178,343.76 |
DisclosureSEC source: 0001179110-10-007827 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,780 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 294 | $54.25 | $15,950.09 |
DisclosureSEC source: 0001179110-10-004237 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,266 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,639 | $54.12 | $359,302.68 |
DisclosureSEC source: 0001179110-10-004237 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,560 Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value · Derivative | 28,700 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001179110-10-003595 · edgar.xml · derivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Shares · 28,700 shares Expires 2020-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,567 on 2/19/2011, 9,566 on 2/19/2012, and 9,567 on 2/19/2013. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003595 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,199 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003595 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,199 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $53.89 | $26,945.00 |
DisclosureSEC source: 0001179110-10-003159 · edgar.xml · nonDerivative · entry 4 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,599 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $53.89 | $21,556.80 |
DisclosureSEC source: 0001179110-10-003159 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,099 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $53.89 | $16,167.30 |
DisclosureSEC source: 0001179110-10-003159 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,499 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,470 | $53.93 | $241,067.10 |
DisclosureSEC source: 0001179110-10-003159 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,799 Read SEC document |
| November 24, 2009 Filed Nov 25, 2009 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,384 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001179110-09-015976 · edgar.xml · derivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,384 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 24, 2009 Filed Nov 25, 2009 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,384 | $54.00 | $74,736.00 |
DisclosureSEC source: 0001179110-09-015976 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,269 Read SEC document |
| November 24, 2009 Filed Nov 25, 2009 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,384 | $53.60 | $74,182.40 |
DisclosureSEC source: 0001179110-09-015976 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2009 Filed Dec 31, 2009 22:02 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,384 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001179110-09-017635 · edgar.xml · derivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,384 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. F2 · shares: The Form 4 filed on November 25, 2009 inadvertently reported that the exercised options were acquired, rather than disposed of, by the reporting person. Read SEC document |
| November 11, 2009 Filed Nov 13, 2009 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 878 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001179110-09-015475 · edgar.xml · derivative · entry 5 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 878 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 11, 2009 Filed Nov 13, 2009 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,274 | $0.00 Strike: $51.91 | $0.00 |
DisclosureSEC source: 0001179110-09-015475 · edgar.xml · derivative · entry 4 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,274 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 11, 2009 Filed Nov 13, 2009 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,152 | $53.50 | $115,132.00 |
DisclosureSEC source: 0001179110-09-015475 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,269 Read SEC document |
| November 11, 2009 Filed Nov 13, 2009 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 878 | $53.24 | $46,744.72 |
DisclosureSEC source: 0001179110-09-015475 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2009 Filed Nov 13, 2009 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,274 | $51.91 | $66,133.34 |
DisclosureSEC source: 0001179110-09-015475 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.89 | $5,089.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 11 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,269 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.92 | $5,092.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 10 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,369 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.97 | $5,096.50 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 9 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,469 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.95 | $5,095.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 8 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,569 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $50.93 | $15,279.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 7 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,669 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $50.94 | $20,376.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 6 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,969 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $50.90 | $20,360.40 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 5 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,369 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.90 | $5,090.11 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 4 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,769 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,800 | $50.90 | $447,920.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,869 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $50.96 | $20,384.40 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,669 Read SEC document |
| November 02, 2009 Filed Nov 4, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,200 | $50.96 | $214,032.00 |
DisclosureSEC source: 0001179110-09-015049 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,069 Read SEC document |
| May 01, 2009 Filed May 4, 2009 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,410 | $41.85 | $142,708.50 |
DisclosureSEC source: 0001104659-09-029084 · a4.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,269 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 01:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 578 | $48.72 | $28,161.32 |
DisclosureSEC source: 0001104659-09-013967 · a4.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,679 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 01:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,120 | $50.58 | $107,229.60 |
DisclosureSEC source: 0001104659-09-013967 · a4.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,257 Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011800 · a4.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Shares · 38,700 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,900 on 02/20/2010, 12,900 on 02/20/2011, and 12,900 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011800 · a4.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,377 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 417 | $54.37 | $22,673.12 |
DisclosureSEC source: 0001104659-09-010778 · a4.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,177 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,582 | $54.94 | $86,915.08 |
DisclosureSEC source: 0001104659-09-010778 · a4.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,594 Read SEC document |
| January 28, 2009 Filed Jan 30, 2009 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,113 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001104659-09-005395 · a4.xml · derivative · entry 6 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,113 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.